|MDACC Study No:||2011-0104 (clinicaltrials.gov NCT No: NCT01476410)|
|Title:||A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma|
|Principal Investigator:||Michelle A. Fanale|
|Treatment Agent:||Adriamycin; Dacarbazine; Doxorubicin; SGN-35|
|Study Description:||The goal of this clinical research study is to learn if SGN-35 (brentuximab |
vedotin), when given before and after chemotherapy with AVD, can help to
control Hodgkin Lymphoma.
Brentuximab vedotin has 2 parts. The first part of the drug is designed to
recognize CD30 and normal cells in the body’s immune system. CD30 is a
molecule on the surface of cells that may make up some types of cancer, such as
Hodgkin lymphoma and anaplastic large cell lymphoma. The second part of the
drug may kill the cells recognized by the first part of brentuximab vedotin.